At the time of writing, Biomarin Pharmaceutical Inc [BMRN] stock is trading at $55.52, down -1.37%. An important factor to consider is whether the stock is rising or falling in short-term value. The BMRN shares have gain 5.63% over the last week, with a monthly amount glided 3.80%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Biomarin Pharmaceutical Inc [NASDAQ: BMRN] stock has seen the most recent analyst activity on November 06, 2025, when Stifel downgraded its rating to a Hold but kept the price target unchanged to $61 for it. Previously, H.C. Wainwright started tracking the stock with Neutral rating on September 08, 2025, and set its price target to $60. On September 03, 2025, Raymond James initiated with an Outperform rating and assigned a price target of $85 on the stock. Oppenheimer upgraded its rating to an Outperform but $98 remained the price target by the analyst firm on February 24, 2025. Wolfe Research started tracking with an Outperform rating for this stock on November 15, 2024, and assigned it a price target of $95. In a note dated October 30, 2024, William Blair downgraded an Mkt Perform rating on this stock.
For the past year, the stock price of Biomarin Pharmaceutical Inc fluctuated between $50.76 and $73.51. Currently, Wall Street analysts expect the stock to reach $82.45 within the next 12 months. Biomarin Pharmaceutical Inc [NASDAQ: BMRN] shares were valued at $55.52 at the most recent close of the market. An investor can expect a potential return of 48.51% based on the average BMRN price forecast.
Analyzing the BMRN fundamentals
According to Biomarin Pharmaceutical Inc [NASDAQ:BMRN], the company’s sales were 3.09B for trailing twelve months, which represents an 5.98% jump. Gross Profit Margin for this corporation currently stands at 0.81% with Operating Profit Margin at 0.2%, Pretax Profit Margin comes in at 0.22%, and Net Profit Margin reading is 0.17%. To continue investigating profitability, this company’s Return on Assets is posted at 0.07, Equity is 0.09 and Total Capital is 0.09. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.1.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 54.56 points at the first support level, and at 53.59 for the second support level. However, for the 1st resistance point, the stock is sitting at 56.44, and for the 2nd resistance point, it is at 57.35.
Ratios To Look Out For
It is important to note that Biomarin Pharmaceutical Inc [NASDAQ:BMRN] has a current ratio of 4.83. On the other hand, the Quick Ratio is 3.10, and the Cash Ratio is 1.57. Considering the valuation of this stock, the price to sales ratio is 3.46, the price to book ratio is 1.76 and price to earnings (TTM) ratio is 20.80.
Transactions by insiders
Recent insider trading involved Burkhart Erin, GVP, Chief Accounting Officer, that happened on May 20 ’25 when 1786.0 shares were sold. Officer, Burkhart Erin completed a deal on May 20 ’25 to buy 1786.0 shares. Meanwhile, EVP, Chief Commercial Officer Hubbard Cristin sold 273.0 shares on May 02 ’25.
